Cholesterol-lowering statins effectively reduce the risk of major cardiovascular events. Myopathy is the most important adverse effect, but its underlying mechanism remains enigmatic. In C2C12 myoblasts, several statin lactones reduced respiratory capacity and appeared to be strong inhibitors of mitochondrial complex III (CIII) activity, up to 84% inhibition. The lactones were in general three times more potent inducers of cytotoxicity than their corresponding acid forms. The Q o binding site of CIII was identified as off-target of the statin lactones. These findings could be confirmed in muscle tissue of patients suffering from statin-induced myopathies, in which CIII enzyme activity was reduced by 18%. Respiratory inhibition in C2C12 myoblasts could be attenuated by convergent electron flow into CIII, restoring respiration up to 89% of control. In conclusion, CIII inhibition was identified as a potential offtarget mechanism associated with statin-induced myopathies.
In Brief
Statin-induced myopathies are the most common side effects of these widely used cholesterol-lowering drugs, affecting millions of patients. Schirris et al. identified the Q o site of mitochondrial complex III as off-target of statin lactones and show possible mechanisms for the attenuation of their inhibitory effect.
INTRODUCTION
Statins (HMG-CoA reductase inhibitors) are cholesterol-lowering drugs that are effective in reducing the risk of major cardiovascular events. They are among the most commonly prescribed drugs worldwide. Although statins are generally well tolerated, myopathies are the most frequent adverse effects, ranging from muscle pain with rates up to 26% to very rare cases of life-threatening rhabdomyolysis (Alfirevic et al., 2014) . Although statin-induced rhabdomyolysis is uncommon, unacceptably high rates were observed with cerivastatin, leading to its withdrawal from the market (Armitage, 2007; Furberg and Pitt, 2001 ).
The risk of developing statin-induced myopathies greatly depends on the type of statin, as illustrated by a recent large-scale post-marketing study (Hoffman et al., 2012) . The differences could at least partially be explained by their relative potencies to inhibit cholesterol synthesis, but are also expected to depend on other effects, such as statin metabolism, drug-drug interactions, statin dose, and lipophilicity (Abd and Jacobson, 2011; Hoffman et al., 2012) . In addition, a number of patient-related risk factors (age, co-morbidities, gender, genetics, ethnicity) have been identified (Abd and Jacobson, 2011; Taha et al., 2014) . This led to the association of statin-induced myopathies with several genetic polymorphisms in various drug transporters, autophagy clearance pathways, and enzymes involved in creatine synthesis (Mangravite et al., 2013; Needham and Mastaglia, 2014; Link et al., 2008; Zeharia et al., 2008; Zhang et al., 2014) . However, not every affected patient is a carrier of such a polymorphism, and additional studies are warranted to determine their significance (Ballard and Thompson, 2013; Floyd et al., 2014; Luzum et al., 2015) . These insights have led to several putative mechanisms to explain statin-induced myopathies, including disturbed calcium homeostasis, decreased protein prenylation, and increased atrogin-1 expression (Abd and Jacobson, 2011; Hanai et al., 2007) .
Another hypothesis suggests a pivotal role for mitochondrial dysfunction, often ascribed to decreased coenzyme-Q 10 synthesis (Marcoff and Thompson, 2007; Sirvent et al., 2008) . However, clinical trials on the effect of coenzyme-Q 10 supplementation gave equivocal results, questioning its pathomechanistic role in statin-induced myopathy (Parker et al., 2013; Sirvent et al., 2008) .
Further widening the range of possible scenarios, most statins are administered in their pharmacologically active acid form, but uridine 5 0 -diphospho-glucuronosyltransferases (UGTs) convert them into the lactone form (Prueksaritanont et al., 2002) . The highly polymorphic nature of these UGTs may further contribute to the large inter-individual differences in conversion rates and ensuing lactone levels, as has been shown for the UGT1A1*28 polymorphism in relation to atorvastatin lactonization (Stormo et al., 2013) . A) Long-term (24 hr) effects of the statins on cell viability were investigated in parallel for determination of the effects of direct statin exposure on ATP production and oxygen consumption. (B) The number of apoptotic (gray) and necrotic (black) C2C12 cells was determined after exposure to the acid (A) or lactone (L) form of eight statins (atorvastatin, ATOR; cerivastatin, CERI; fluvastatin, FLUV; lovastatin, LOVA; pitavastatin, PITA; pravastatin, PRAV; rosuvastatin, ROSU; and simvastatin, SIMV). The total number of cytotoxic (apoptotic and necrotic) cells was expressed as percentage of the total number of cells present, followed by determination of the cytotoxicity EC 50 value. (C) Basal respiratory rates were determined after acute application of the statin acid (black) or lactone (gray) form at their cytotoxic EC 50 concentration, or at least two times (2-8 times) the EC 50 value of the corresponding lactone (if EC 50 > 300). Data are expressed as percentage of the vehicle (42 ± 2 pmol O 2 /s/10 6 cells).
(D) Maximal ATP production was measured in permeabilized C2C12 cells after acute exposure to the statin acid (black) or lactone (gray) form at concentrations described under (C). Data are expressed as percentage of vehicle (29 ± 3 nmol/hr/mU CS). ND: not determined due to precipitation in this particular buffer.
(E-H) Under conditions similar to the ATP production measurements the effects of the acid (black) or lactone (gray) form of the indicated statin on (E) CI-, (F) CII-, (G) glycerol-3-phosphate dehydrogenase (G3PDH)-, or (H) CIV-driven oxygen consumption were examined. Data are expressed as percentage of
(legend continued on next page)
Here, we demonstrate a molecular off-target mechanism that can explain mitochondrial-related myotoxicity by several statins.
RESULTS AND DISCUSSION
Compared to Their Acid Forms, Statin Lactones Are More Potent in Inducing Cytotoxicity and Reducing Respiration and Mitochondrial ATP Production To evaluate the role of statin-induced mitochondrial dysfunction, we explored the cytotoxic mechanism in C2C12 myoblasts. This cell model was chosen because it displays similar cellular features as those observed during statin-induced myotoxicity in humans, such as lowered protein prenylation and N-linked glycosylation levels, unchanged cellular cholesterol and coenzyme Q levels, and decreased antrogin-1-mediated Akt phosphorylation (Mullen et al., 2010 (Mullen et al., , 2011 . Since previous work indicated that the statin lactones are more potent inducers of cytotoxicity than their acid counterparts (Skottheim et al., 2008) , both the acid and lactone forms of eight statins were investigated in this study. In agreement with the above study, long-term statin exposure ( Figure 1A ) revealed a higher cytotoxic potency (EC 50 ) for seven lactones as compared to their acid counterparts ( Figure 1B ). Also in terms of cytotoxic efficacy, the lactone forms of six statins scored significantly higher than their acid counterparts ( Figure 1B ). With the exception of lovastatin lactone, apoptosis appeared to be the major mechanism of cytotoxicity for both lactones and acids ( Figure 1B ). To avoid possible interference of adaptive responses, acute statin exposure was analyzed, which revealed that the lactone forms of atorvastatin, cerivastatin, and pitavastatin caused an immediate decrease in the basal oxygen consumption rate of resting cells ( Figure 1C ). This observation was in agreement with the previously reported decrease in CI-driven respiration in statin-treated volunteers (Sirvent et al., 2012) and indicated a direct inhibitory effect on the mitochondrial ATP production machinery (Figure 1C) . Corroborating this conclusion, the lactone forms of atorvastatin, cerivastatin, and simvastatin proved to be much more potent than their acid counterparts in acutely decreasing the maximal rate of mitochondrial ATP production in permeabilized C2C12 myoblasts ( Figure 1D ).
Statin Lactones Specifically Inhibit the Enzymatic Activity of CIII of the Respiratory Chain
To address the possible involvement of individual respiratory chain complexes in the inhibitory action of statins, we went on to measure the effect of acids and lactones on the maximal respiratory rates in the presence of complex-specific substrates. Compared to their acid counterparts, the lactones of atorvastatin, cerivastatin, and pitavastatin significantly inhibited maximal CI-, CII-, and glycerol-3-phosphate dehydrogenase (G3PDH)-driven respiration ( Figures 1E-1G ). The latter activity was also significantly inhibited by the lactones of lovastatin and simvastatin. Intriguingly, the acid form of fluvastatin acid inhibited CIand CII-driven respiration; however, it only marginally affected G3PDH-driven respiration ( Figures 1E-1G ). Importantly, none of the statins significantly inhibited CIV-driven respiration (Figure 1H ). Statin exposure did not affect the mitochondrial membrane potential, thus excluding their action as a mitochondrial uncoupler (data not shown). These results pointed toward a specific inhibitory effect of several lactone statins on the enzymatic activity of mitochondrial CIII. Indeed, direct testing of the effects on the individual enzymatic activities of all five complexes revealed significant inhibition by 5 out of 8 statin lactones only for complex III (Figures S1A-S1E). For atorvastatin lactone we noted a much stronger effect on ATP production rate ( Figure 1D ) than on the other activities involving complex III ( Figures 1E-1G ), which may indicate an additional off-target for this compound. However, we did not further explore this possibility as it was beyond the scope of this study.
For a better comparison of the effect of the different statins on CIII, we measured ubiquinol:cytochrome c oxidoreductase activity in broken C2C12 mitochondria after acute statin exposure at a fixed concentration for all compounds ( Figure 2A ). As expected, CIII inhibition by cerivastatin, pitavastatin, lovastatin, and simvastatin was much more pronounced, whereas also in this assay fluvastatin acid was without effect. Interestingly, the lactone that exhibited the strongest inhibition was that of cerivastatin, which was withdrawn from the market because of its high rhabdomyolysis activity. The inhibitory effect of the lactones was not mimicked by the acids and seemed to depend, at least partially, on their lipophilicity, because no inhibition was observed with lactones with an intermediate (e.g., fluvastatin) or low (e.g., pravastatin and rosuvastatin) lipophilicity (see also Abd and Jacobson, 2011; Taha et al., 2014) . Finally, we could confirm reversibility of CIII inhibition by showing recovery of activity after washing of a statin-treated mitochondrial fraction ( Figure S1F ).
Statin Lactones Inhibit the Q o Site of CIII
Since CIII contains two potential binding sites (Q o and Q i ) (Brandt and Trumpower, 1994) for the statin lactones ( Figure 2B ), we further explored their inhibitory mechanism of interaction by in silico off-target predictions with the structure-based pharmacophore fingerprint method KRIPO (Wood et al., 2012) . An offtarget should have a pocket comparable to the pharmacological target in order to bind the drug. Therefore, pharmacophore models of statin (sub-)pockets of HMG-CoA reductase were constructed ( Figure S2A) . Next, the sub-binding pockets derived from these models were compared with a library of more than 300,000 (sub-)binding pockets revealing high similarity to the sub-binding pockets of the Q o and Q i binding sites of CIII. Both sites are involved in the transfer of electrons from coenzyme Q to cytochrome c involving cytochromes c 1 and b ( Figure 2B ). Docking predicted binding of the statin lactone form ( Figure 2C) , to compare differences between apoptotic and necrotic levels (within bars, only B), or to compare differences between acids and lactones (on top of connecting lines) *p < 0.05, **p < 0.01, ***p < 0.001. Mean ± SEM; n = 3 independent experiments.
but not the acid form ( Figure 2D ) to the Q o site. Acid binding is most likely hampered due to repulsive interactions with Glu-272. This prediction is supported by the previously published observation that the ester of crocasin, which resembles the lactone form of statins, but not the acid form, can bind to the Q o site of CIII (Crowley et al., 2008) . Docking of statins into the Q i site was also feasible ( Figures  S2D and S2E) . Therefore, we went on to determine the statin binding site within CIII experimentally by measuring the effects of simvastatin, one of the currently most widely used statins, on the ubiquinol-induced reduction of cytochromes c 1 and b in isolated heart bovine mitochondria (Brandt et al., 1988) (Figure 2B ). Simvastatin lactone inhibited the reduction of cytochrome c 1 ( Figure 2E ), but not b ( Figure 2F ). Importantly, this inhibition pattern resembled that of the bona fide Q o site inhibitor myxothiazol ( Figure 2G ) characterized by a lowered reduction of cytochrome c 1 but an unaffected reduction of cytochrome b, which is reduced by reversed electron flow through the Q i site under these conditions (Brandt et al., 1988) . In contrast, simvastatin lactone did not mimic the pattern of the Q i site . Simvastatin lactone or acid was added at the indicated concentration, followed by the addition of 50 mM decylubiquinol (DUH 2 ). The difference spectrum obtained was used to calculate the reduction state of (E) cytochrome c 1 and (F) cytochrome b. (G and H) Similar to the difference spectra obtained with the statins, spectra were also recorded with and without known CIII inhibitors (G) myxothiazol (myxo, 100 mM), a Q o site inhibitor, and (H) antimycin A (AA, 25 mM), a Q i site inhibitor. The values at 553 nm and 562 nm obtained with dithionite were set at 100% to which the values presented on top of the spectra were related. For statin abbreviations see Figure 1 . Statistical analysis: one-way ANOVA with Bonferroni post hoc analysis, **p < 0.01, ***p < 0.001. Mean ± SEM; n = 3 independent experiments.
inhibitor antimycin A characterized by increased cytochrome b reduction under the conditions applied ( Figures 2F and 2H) . The acid form, however, failed to affect the reduction of both cytochromes ( Figure 2E ). This reduction pattern indicates (Brandt et al., 1988 ) that statin lactones act primarily at the Q o site to exert their inhibitory effect on mitochondrial ATP production.
Mitochondrial CIII Activity Is Decreased in Muscle of Patients with Statin-Induced Myopathies
To assess the in vivo relevance of our in vitro observations, we analyzed muscle biopsies from 37 patients with statin-induced myopathies (for study design see Supplemental Experimental Procedures and for detailed patient information see Table S1 ). This analysis revealed a significant decrease in CIII enzyme activity ( Figures 3A-3D ) and mitochondrial ATP production capacity ( Figure 3E ), of which the former remained statistically significant after correction for age and gender (Table S2) . No relation was observed with co-medication, BMI, smoking pattern, or alcohol use (for an overview of these variables, see Table S1 ). On the other hand, a significant correlation was observed between CIII activity and clinical presentation (r s = À0.371, p = 0.024), with patients with proximal muscle weakness and rhabdomyolysis showing the smallest and largest decrease in CIII activity, respectively. Subsequently, we used stored muscle biopsy material of 14 patients who gave additional informed consent to determine the total amount of statin (acid and lactone). Relative to the calculated steady-state plasma concentration, a marked accumulation of the lipophilic statins atorvastatin and simvastatin was observed ( Figure 3F ), as has been hypothesized previously 2,000 (A-F) Muscle biopsies were obtained, following informed consent, from healthy controls (CT) and patients (PAT) with statin-induced myopathies and were used for preparation of a mitochondrial-enriched fraction. (A-D) Enzyme activities of CI to CIV were measured in a snap-frozen mitochondrial fraction and normalized to citrate synthase (CS) content. (E) ATP production capacity was measured in a freshly prepared mitochondrial fraction and normalized to CS. Statistical analysis: two-sided Student's t test with Welch's correction when variances were significantly different according to F-test, *p < 0.05, **p < 0.01, mean ± SD, n as indicated in figure. (F) Muscle statin accumulation is expressed as the muscle/plasma concentration ratio. Muscle concentrations (nmol/kg wet weight) were determined in muscle homogenates of 14 patients in total, using four different statins. Free plasma steady-state concentrations (nmol/l) were calculated from the administered dose using first-order kinetics. Ratios were 0.82 for pravastatin, 6 ± 2 for rosuvastatin, 300 ± 160 for atorvastatin, and 490 ± 120 for simvastatin. For statin abbreviations see Figure 1 . Statistical analysis: one-way ANOVA, Bonferroni post hoc analysis, *p < 0.05, mean ± SEM, n as indicated in figure. Lipophilicity of the different statins is expressed as the logD value. (Distribution coefficients were adapted from White, 2002 .) See Tables S1, S2, S4, and S5 for more detailed patient characteristics and age-and gender-corrected statistical analysis. (E) Primary skin fibroblasts of two healthy controls (C5120, black; C6855, gray) and three CIII-deficient patients (P5847, red; P6147, blue; P6748, green) were isolated and cultured.
(F) Skin fibroblasts were exposed for 24 hr to the indicated statins at concentrations ranging up to 300 mM.
(legend continued on next page) (Skottheim et al., 2008) . On the other hand, the more hydrophilic statins, pravastatin and rosuvastatin, displayed noticeably lower accumulation values ( Figure 3F ).
Statin-Induced Respiration Inhibition Is Attenuated by
Reduced Coenzyme Q Next, we explored strategies to mitigate the off-target effects of statins. Based on the present finding that lactones act on the Q o site of CIII to inhibit CI-, CII-, and G3PDH-driven respiration, we investigated the effect of an additional increase of the endogenous pool of reduced coenzyme Q through concomitant stimulation of either the G3PDH or b-oxidation pathway (Figure 4A) . Such a concomitant stimulation results in a convergent electron flow into coenzyme Q (Gnaiger, 2009) , as could also be observed with vehicle-treated C2C12 myoblasts, when comparing the combined substrate respiration to the single substrate respiratory rates (Table S3 ). The data obtained show a partial (cerivastatin lactone and pitavastatin lactone) to almost complete (atorvastatin lactone and simvastatin lactone) reversal of the inhibitory effect of these lactones on CI-and CII-driven oxygen consumption ( Figures 4B and 4C ). As expected, convergent electron flow did not alter CIV-driven oxygen consumption (Figure 4D ). This demonstrates that the degree of lactone inhibition of Q o depends on the ambient reduced coenzyme Q level competing for the same binding site. Moreover, these results may shed light on the association between statin-induced myopathies and carnitine-palmitoyltranferase-2 (CPT2) dysfunction (DiNicolantonio, 2012; Hur et al., 2014; Vladutiu et al., 2006) . CPT2 is involved in mitochondrial fatty acid uptake, and its deficiency will lead to a decreased availability of fatty acids for b-oxidation. According to our model, this leads to a decreased convergent electron flow and, thus, to a reduced ability to reverse lactone inhibition of CIII. In agreement with this hypothesis, stimulation of fatty acid uptake by supplementation of L-carnitine was found to ameliorate statin-induced muscle and liver damage (Arduini et al., 2004) . Our present observations provide an experimental rationale for treatment of patients with statin-induced myopathies with therapeutics that increase convergent electron flow.
Statin-Induced Cytotoxicity Is Increased in Primary Skin
Fibroblasts of CIII-Deficient Patients Next, we addressed the possibility that patients with a deficiency of CIII are at risk of statin-induced myopathies. Statininduced cytotoxicity was evaluated in primary human skin fibroblasts of two healthy controls and three CIII-deficient patients ( Figures 4E and 4F ). The emerging picture is that patient fibroblasts are more sensitive to the lactone forms of cerivastatin, lovastatin, and pitavastatin than the control fibroblasts ( Figure 4G , right panel). On the other hand, no such difference in sensitivity was observed with any of the acids tested (Figure 4G, left panel) .
Conclusions
In conclusion, we demonstrate that the Q o site of respiratory CIII is inhibited by several statin lactones and provide evidence for an association between this off-target effect and statin-induced myopathies. Consequently, polymorphisms of UGTs, the enzymes converting statin acids into lactones, and CIII could be predisposing factors in statin-induced myopathies. We showed that both G3PDH and b-oxidation stimulation can prevent statin-induced respiratory inhibition, providing a rationale for therapeutic intervention.
EXPERIMENTAL PROCEDURES Analysis of Cell Death
Twenty-four hours prior to statin treatment, C2C12 myoblasts or primary skin fibroblasts were seeded in 384-well black/clear imaging plates (Santa Cruz Biotechnology) and exposed to the indicated statins up to maximum solubility (300 mM). After 24 hr exposure, nuclei were stained for cell viability and imaged with a high-throughput microscope. See Supplemental Experimental Procedures for more details.
Analysis of Cellular and Mitochondrial Respiration
For measurement of the cellular respiration rate, 1.5 3 10 6 C2C12 cells were resuspended in mitochondrial respiration medium MiR05 and transferred to the thermostatted (37 C) chamber of an Oxygraph-2k equipped with DatLab 5 recording and analysis software (Oroboros Instruments). Mitochondrial respiration driven by the separate respiratory chain complexes was measured after digitonin permeabilization (10 mg/1 3 10 6 cells) of the cell membrane in MiR05 containing complex-specific substrates and 4 mM ADP (Kuznetsov et al., 2008) . See Supplemental Experimental Procedures for more details about the specific substrates used.
Mitochondrial ATP Production Capacity C2C12 cells were resuspended in PBS with 3% BSA (Fisher Scientific), to a final density of 10 3 10 6 cells/ml. Mitochondrial ATP production from pyruvate was measured in the presence of digitonin (200 mg/1 3 10 6 cells) in duplicate, as described previously (Janssen et al., 2006; Renkema et al., 2015) . See Supplemental Experimental Procedures for more details.
Enzyme Activity of Individual OXPHOS Complexes C2C12 pellets of 20 3 10 6 cells were snap frozen in liquid nitrogen and kept at À80 C until use. For preparation of the mitochondrial fractions, tissues and cells were homogenized as described in the Supplemental Experimental Procedures. In addition, for the CV measurements, the 600 g supernatant containing the mitochondria was pelleted at 14,000 g for 10 min, resuspended in 10 mM Tris-HCl (pH 7.6), and snap frozen in aliquots. Enzyme activity of OXPHOS complexes was measured spectrophotometrically in duplicate in the absence and presence of the different statins, as described previously (Janssen et al., 2007; Mourmans et al., 1997; Rodenburg, 2011) . See Supplemental Experimental Procedures for more details.
Complex III Cytochromes Reduction
The ubiquinol-induced reduction of CIII cytochromes c 1 and b was measured in a preparation of isolated heart bovine mitochondria (Brandt et al., 1988) using the end-on photomultiplier setup of a Lambda 18 UV-Vis spectrophotometer (Perkin Elmer). See Supplemental Experimental Procedures for more details.
(G) Cytotoxicity EC 50 values were determined as described in Figure In Silico Off-Target Prediction The structure-based pharmacophore fingerprint method KRIPO (Wood et al., 2012) was used to detect (partial) similarities between HMG-CoA reductase and protein structures present in the RCSB Protein Data Bank (Berman et al., 2000) (http://www.rcsb.org) in order to find new statin off-targets (e.g., targets other than the pharmaceutical target that underlie the toxic effects). First, pharmacophore representations of the HMG-CoA reductase statin (sub-)pockets were generated and were compared to all protein (sub-)pocket entries of the PDB (March 2013). See Supplemental Experimental Procedures for more details.
Docking of Statins
To explore possible binding modes between statins and CIII, both the acid and lactone forms were docked into the Q o and Q i binding pockets of CIII. Docking was performed using Molecular Operating Environment (MOE) software 2012.10 (Chemical Computing Group, Inc.) following the rigid receptor protocol. For the docking, an X-ray structure of CIII was selected, in which the Q o binding site is occupied by a iodinated analog of the polypetide crocacin-D and the Q i site by coenzyme Q (PDB: 3CWB) (Crowley et al., 2008) ( Figures  S2B and S2C ).
Patient Muscle Biopsies
Thirty-seven patients with statin-induced myopathy were retrospectively selected (2008) (2009) (2010) (2011) (2012) (2013) ) from a cohort of 1,386 patients from whom a muscle biopsy (m. quadriceps femoris) was taken after consulting our center with muscle symptoms. The study was carried out in the Netherlands in accordance with the applicable rules concerning the review of research ethics committees (Commissie Mensgebonden Onderzoek Regio Arnhem-Nijmegen) and informed consent. Results obtained for diagnostic purposes were anonymized before use. See Supplemental Experimental Procedures for more details about the study design.
Determination and Calculation of Muscle and Plasma Statin Concentrations
Muscle tissue homogenates of 14 patients with statin-induced myopathies were used. Statin concentrations were determined using liquid chromatography-tandem mass spectrometry. Free plasma statin steady-state concentrations of individual patients were estimated using first-order pharmacokinetic equations. See Supplemental Experimental Procedures for more details on parameters used for these calculations. 
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